{"success":true,"data":{"pressRelease":{"id":"23031","rtpr_id":"nGNX6vgspY","ticker":"RYTM","exchange":"NASDAQ","all_tickers":["RYTM"],"title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference","author":"Globe Newswire","published_at":"2026-05-06T12:00:00.833Z","article_body":"BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:\nRYTM), a global commercial-stage biopharmaceutical company focused on\ntransforming the lives of patients living with rare neuroendocrine diseases,\ntoday announced that David Meeker, M.D., Chairman, President and Chief\nExecutive Officer, will participate in a fireside chat at the upcoming Bank of\nAmerica Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m. PT in\nLas Vegas.\n\nThe fireside chat will be webcasted and available under “Events &\nPresentations” in the Investor Relations section of the Company’s website\nat www.rhythmtx.com. A replay of the webcast will be available on the Rhythm\nwebsite for 30 days following the presentation.\n\nAbout Rhythm Pharmaceuticals \nRhythm is a commercial-stage biopharmaceutical company committed to\ntransforming the lives of patients and their families living with rare\nneuroendocrine diseases. Rhythm’s lead asset, IMCIVREE(®) (setmelanotide),\nan MC4R agonist designed to treat hyperphagia and severe obesity, is approved\nby the U.S. Food and Drug Administration (FDA) to reduce excess body weight\nand maintain weight reduction long term in adult and pediatric patients aged 4\nyears and older with acquired hypothalamic obesity, adult and pediatric\npatients 2 years of age and older with syndromic or monogenic obesity due to\nBardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin\n(POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1),\ndeficiency or leptin receptor (LEPR) deficiency. Both the European Commission\n(EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA)\nhave authorized setmelanotide for the treatment of obesity and the control of\nhunger associated with genetically confirmed BBS or genetically confirmed\nloss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR\ndeficiency in adults and children 2 years of age and above. The European\nCommission (EC) has authorized setmelanotide for the treatment of obesity and\ncontrol of hunger in patients 4 years of age and above with acquired\nhypothalamic obesity. Additionally, Rhythm is advancing a broad clinical\ndevelopment program for setmelanotide in other rare diseases, as well as\ninvestigational MC4R agonists bivamelagon and RM-718, and a preclinical suite\nof small molecules for the treatment of congenital hyperinsulinism. Rhythm’s\nheadquarters is in Boston, MA.\n\nSetmelanotide Indication \nIn the United States, setmelanotide is indicated to reduce excess body weight\nand maintain weight reduction long term in adults and pediatric patients aged\n4 years and older with acquired hypothalamic obesity, in adult and pediatric\npatients aged 2 years and older with syndromic or monogenic obesity due to\nBardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein\nconvertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR)\ndeficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1,\nor LEPR genes that are interpreted as pathogenic, likely pathogenic, or of\nuncertain significance (VUS).\n\nIn the European Union and the United Kingdom, setmelanotide is indicated for\nthe treatment of obesity and the control of hunger associated with genetically\nconfirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency\nor biallelic LEPR deficiency in adults and children 2 years of age and above.\nIn the European Union and the United Kingdom, setmelanotide should be\nprescribed and supervised by a physician with expertise in obesity with\nunderlying genetic etiology.\n\nLimitations of Use\n\nSetmelanotide is not indicated for the treatment of patients with the\nfollowing conditions as setmelanotide would not be expected to be effective:\n* Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1,\nor LEPR variants classified as benign or likely benign\n* Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or\nLEPR deficiency, including obesity associated with other genetic syndromes and\ngeneral (polygenic) obesity.\nImportant Safety Information\n\nCONTRAINDICATIONS\n\nPrior serious hypersensitivity to setmelanotide or any of the excipients in\nIMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been\nreported.\n\nWARNINGS AND PRECAUTIONS\n\nDisturbance in Sexual Arousal: Spontaneous penile erections and increased\nfrequency of penile erections in males have occurred. Inform patients that\nthese events may occur and instruct patients who have an erection lasting\nlonger than 4 hours to seek emergency medical attention.\n\nDepression and Suicidal Ideation: Depression and suicidal ideation have\noccurred. Monitor patients for new onset or worsening depression or suicidal\nthoughts or behaviors. Consider discontinuing IMCIVREE if patients experience\nsuicidal thoughts or behaviors, or clinically significant or persistent\ndepression symptoms occur.\n\nHypersensitivity Reactions: Serious hypersensitivity reactions (e.g.,\nanaphylaxis) have been reported. If suspected, advise patients to promptly\nseek medical attention and discontinue IMCIVREE.\n\nSkin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New\nMelanocytic Nevi: Generalized or focal increases in skin pigmentation occurred\nin the majority of IMCIVREE-treated patients. IMCIVREE may also cause\ndevelopment of new melanocytic nevi or darkening of pre-existing nevi. Perform\na full body skin examination prior to initiation and periodically during\ntreatment to monitor pre-existing and new pigmented lesions.\n\nAcute Adrenal Insufficiency with Acquired HO: Patients with acquired HO and\nsecondary adrenal insufficiency reported serious adverse reactions related to\nacute adrenal insufficiency in 5% of IMCIVREE-treated patients and no\nplacebo-treated patients. In patients with secondary adrenal insufficiency,\nmonitor for clinical signs of acute adrenal insufficiency.\n\nSodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus:\nPatients with acquired HO and concomitant central diabetes insipidus\n(DI)/arginine vasopressin (AVP) deficiency reported hyponatremia in 6% of\nIMCIVREE-treated patients and 2% of placebo-treated patients and hypernatremia\nin 5% of IMCIVREE-treated patients and 4% of placebo-treated patients. Monitor\nserum sodium levels with changes in fluid intake and hydration status. Adjust\nthe doses of concomitant therapies for DI/AVP deficiency as needed.\n\nADVERSE REACTIONS\n\nMost common adverse reactions (incidence ≥20% in at least 1 indication)\nincluded skin hyperpigmentation, injection site reactions, nausea, headache,\ndiarrhea, abdominal pain, vomiting, depression, and spontaneous penile\nerection.\n\nUSE IN SPECIFIC POPULATIONS\n\nTreatment with IMCIVREE is not recommended when breastfeeding. Discontinue\nIMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh\nthe potential risks to the fetus.\n\nTo report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1\n(833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. See\nsection 4.8 of the Summary of Product Characteristics\n(https://www.globenewswire.com/Tracker?data=RTnb6V_0QcgM_EirgKlvMSgEt9LGA66XLlnbarH2vZAAnZYRtagbMAFRi3I5BNh0MPFKtcKY-Z1bbK4UdqV78vNDPpapjO7u3mAAJy_uG9EsvckGFYijB4GMMrDBdGq-WKWW18oOD3yTs7SeRzcky1s6InfNtp7ghl0qQYzhZxFkRat6EaaXJ4DBOtVTjgyI22dKe10maR-IuNVJIdE676tJCJd-eto_--d5L-XsWziQJQmhGTRYL0_s2xJ72jhcZ9lyGRYLb8O3a0w_FqkJjWOtkRBbf1spAPEv61x6b54cyOkvM4QqGe14xLbpBPKvKMU__CzNU2Bet80LNqC1rdTJq0RspTIjR14yHKL08OIpsHPF00pBwQIRNyb8z56XMENw3YrHCzJryFzttAwdfxgsFVjQyCDebWPI0R__Q61G0XITDoUtP3eRnyh4sBwtkwXUJMUoeRqDgkxAkrJBCpkh9HaOGYCycNS5-_jsC0ZneHD-VQrQvqJQrHvM3CFTuzdXVmlKOKdN95I6pjW5RKpKq2Jv8FQD6SKngN9ihXfQR-ZuyUFgr1AyxALNivJJzbT32ki6uvzy3IOxyaXATi_tB0uVAy1EiG3gJzt1yOykftDLaKRNsQDrnpQGwwu_wqr8hNy0GHOFt5AA-WVYyD0l77YGpvEFFF3dPi2YRFHLeoyJo4CXWfqnKbXwBY1lseqqaAynIzfEJWvNHmmP7zpnB9hJszakGZstSomG7N0FnFfwr6qj42f3h3CPh39Vt6KvLikjrQ9Oe3ZQinfT_w==)\nfor information on reporting suspected adverse reactions in Europe.\n\nPlease see the full Prescribing Information for additional Important Safety\nInformation.\n\nForward-looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements contained\nin this press release that do not relate to matters of historical fact should\nbe considered forward-looking statements, including, without limitation,\nstatements regarding the safety, efficacy, potential benefits of, and clinical\ndesign or progress of any of our products or product candidates at any dosage\nor in any indication; our participation in upcoming events and presentations,\nincluding at the upcoming Bank of America Global Healthcare Conference,\nincluding the content, date and timing of any of the foregoing. Statements\nusing words such as “expect”, “anticipate”, “believe”, “may”,\n“will” and similar terms are also forward-looking statements. Such\nstatements are subject to numerous risks, uncertainties and other important\nfactors, including those discussed under the caption “Risk Factors” in\nRhythm’s Quarterly Report on Form 10-Q for the three months ended March 31,\n2026, and our other filings with the Securities and Exchange Commission.\nExcept as required by law, we undertake no obligations to make any revisions\nto the forward-looking statements contained in this release or to update them\nto reflect events or circumstances occurring after the date of this release,\nwhether as a result of new information, future developments or otherwise.\n\nCorporate Contacts: \nDavid Connolly \nHead of Investor Relations and Corporate Communications \nRhythm Pharmaceuticals, Inc. \n857-264-4280 \ndconnolly@rhythmtx.com  \n\nKate Walsh\nDirector, Corporate Communications\nRhythm Pharmaceuticals, Inc. \n(857) 264-4280\nkwalsh@rhythmtx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b767aaa5-9915-465f-9233-d97757f4e387)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6vgspY","title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference","author":"Globe Newswire","ticker":"RYTM","created":"2026-05-06T12:00:00.833Z","tickers":["RYTM"],"exchange":"NASDAQ","article_body":"BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:\nRYTM), a global commercial-stage biopharmaceutical company focused on\ntransforming the lives of patients living with rare neuroendocrine diseases,\ntoday announced that David Meeker, M.D., Chairman, President and Chief\nExecutive Officer, will participate in a fireside chat at the upcoming Bank of\nAmerica Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m. PT in\nLas Vegas.\n\nThe fireside chat will be webcasted and available under “Events &\nPresentations” in the Investor Relations section of the Company’s website\nat www.rhythmtx.com. A replay of the webcast will be available on the Rhythm\nwebsite for 30 days following the presentation.\n\nAbout Rhythm Pharmaceuticals \nRhythm is a commercial-stage biopharmaceutical company committed to\ntransforming the lives of patients and their families living with rare\nneuroendocrine diseases. Rhythm’s lead asset, IMCIVREE(®) (setmelanotide),\nan MC4R agonist designed to treat hyperphagia and severe obesity, is approved\nby the U.S. Food and Drug Administration (FDA) to reduce excess body weight\nand maintain weight reduction long term in adult and pediatric patients aged 4\nyears and older with acquired hypothalamic obesity, adult and pediatric\npatients 2 years of age and older with syndromic or monogenic obesity due to\nBardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin\n(POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1),\ndeficiency or leptin receptor (LEPR) deficiency. Both the European Commission\n(EC) and the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA)\nhave authorized setmelanotide for the treatment of obesity and the control of\nhunger associated with genetically confirmed BBS or genetically confirmed\nloss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR\ndeficiency in adults and children 2 years of age and above. The European\nCommission (EC) has authorized setmelanotide for the treatment of obesity and\ncontrol of hunger in patients 4 years of age and above with acquired\nhypothalamic obesity. Additionally, Rhythm is advancing a broad clinical\ndevelopment program for setmelanotide in other rare diseases, as well as\ninvestigational MC4R agonists bivamelagon and RM-718, and a preclinical suite\nof small molecules for the treatment of congenital hyperinsulinism. Rhythm’s\nheadquarters is in Boston, MA.\n\nSetmelanotide Indication \nIn the United States, setmelanotide is indicated to reduce excess body weight\nand maintain weight reduction long term in adults and pediatric patients aged\n4 years and older with acquired hypothalamic obesity, in adult and pediatric\npatients aged 2 years and older with syndromic or monogenic obesity due to\nBardet-Biedl syndrome (BBS) or Pro-opiomelanocortin (POMC), proprotein\nconvertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR)\ndeficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1,\nor LEPR genes that are interpreted as pathogenic, likely pathogenic, or of\nuncertain significance (VUS).\n\nIn the European Union and the United Kingdom, setmelanotide is indicated for\nthe treatment of obesity and the control of hunger associated with genetically\nconfirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency\nor biallelic LEPR deficiency in adults and children 2 years of age and above.\nIn the European Union and the United Kingdom, setmelanotide should be\nprescribed and supervised by a physician with expertise in obesity with\nunderlying genetic etiology.\n\nLimitations of Use\n\nSetmelanotide is not indicated for the treatment of patients with the\nfollowing conditions as setmelanotide would not be expected to be effective:\n* Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1,\nor LEPR variants classified as benign or likely benign\n* Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or\nLEPR deficiency, including obesity associated with other genetic syndromes and\ngeneral (polygenic) obesity.\nImportant Safety Information\n\nCONTRAINDICATIONS\n\nPrior serious hypersensitivity to setmelanotide or any of the excipients in\nIMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been\nreported.\n\nWARNINGS AND PRECAUTIONS\n\nDisturbance in Sexual Arousal: Spontaneous penile erections and increased\nfrequency of penile erections in males have occurred. Inform patients that\nthese events may occur and instruct patients who have an erection lasting\nlonger than 4 hours to seek emergency medical attention.\n\nDepression and Suicidal Ideation: Depression and suicidal ideation have\noccurred. Monitor patients for new onset or worsening depression or suicidal\nthoughts or behaviors. Consider discontinuing IMCIVREE if patients experience\nsuicidal thoughts or behaviors, or clinically significant or persistent\ndepression symptoms occur.\n\nHypersensitivity Reactions: Serious hypersensitivity reactions (e.g.,\nanaphylaxis) have been reported. If suspected, advise patients to promptly\nseek medical attention and discontinue IMCIVREE.\n\nSkin Hyperpigmentation, Darkening of Pre-existing Nevi, and Development of New\nMelanocytic Nevi: Generalized or focal increases in skin pigmentation occurred\nin the majority of IMCIVREE-treated patients. IMCIVREE may also cause\ndevelopment of new melanocytic nevi or darkening of pre-existing nevi. Perform\na full body skin examination prior to initiation and periodically during\ntreatment to monitor pre-existing and new pigmented lesions.\n\nAcute Adrenal Insufficiency with Acquired HO: Patients with acquired HO and\nsecondary adrenal insufficiency reported serious adverse reactions related to\nacute adrenal insufficiency in 5% of IMCIVREE-treated patients and no\nplacebo-treated patients. In patients with secondary adrenal insufficiency,\nmonitor for clinical signs of acute adrenal insufficiency.\n\nSodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus:\nPatients with acquired HO and concomitant central diabetes insipidus\n(DI)/arginine vasopressin (AVP) deficiency reported hyponatremia in 6% of\nIMCIVREE-treated patients and 2% of placebo-treated patients and hypernatremia\nin 5% of IMCIVREE-treated patients and 4% of placebo-treated patients. Monitor\nserum sodium levels with changes in fluid intake and hydration status. Adjust\nthe doses of concomitant therapies for DI/AVP deficiency as needed.\n\nADVERSE REACTIONS\n\nMost common adverse reactions (incidence ≥20% in at least 1 indication)\nincluded skin hyperpigmentation, injection site reactions, nausea, headache,\ndiarrhea, abdominal pain, vomiting, depression, and spontaneous penile\nerection.\n\nUSE IN SPECIFIC POPULATIONS\n\nTreatment with IMCIVREE is not recommended when breastfeeding. Discontinue\nIMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh\nthe potential risks to the fetus.\n\nTo report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1\n(833) 789-6337 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. See\nsection 4.8 of the Summary of Product Characteristics\n(https://www.globenewswire.com/Tracker?data=RTnb6V_0QcgM_EirgKlvMSgEt9LGA66XLlnbarH2vZAAnZYRtagbMAFRi3I5BNh0MPFKtcKY-Z1bbK4UdqV78vNDPpapjO7u3mAAJy_uG9EsvckGFYijB4GMMrDBdGq-WKWW18oOD3yTs7SeRzcky1s6InfNtp7ghl0qQYzhZxFkRat6EaaXJ4DBOtVTjgyI22dKe10maR-IuNVJIdE676tJCJd-eto_--d5L-XsWziQJQmhGTRYL0_s2xJ72jhcZ9lyGRYLb8O3a0w_FqkJjWOtkRBbf1spAPEv61x6b54cyOkvM4QqGe14xLbpBPKvKMU__CzNU2Bet80LNqC1rdTJq0RspTIjR14yHKL08OIpsHPF00pBwQIRNyb8z56XMENw3YrHCzJryFzttAwdfxgsFVjQyCDebWPI0R__Q61G0XITDoUtP3eRnyh4sBwtkwXUJMUoeRqDgkxAkrJBCpkh9HaOGYCycNS5-_jsC0ZneHD-VQrQvqJQrHvM3CFTuzdXVmlKOKdN95I6pjW5RKpKq2Jv8FQD6SKngN9ihXfQR-ZuyUFgr1AyxALNivJJzbT32ki6uvzy3IOxyaXATi_tB0uVAy1EiG3gJzt1yOykftDLaKRNsQDrnpQGwwu_wqr8hNy0GHOFt5AA-WVYyD0l77YGpvEFFF3dPi2YRFHLeoyJo4CXWfqnKbXwBY1lseqqaAynIzfEJWvNHmmP7zpnB9hJszakGZstSomG7N0FnFfwr6qj42f3h3CPh39Vt6KvLikjrQ9Oe3ZQinfT_w==)\nfor information on reporting suspected adverse reactions in Europe.\n\nPlease see the full Prescribing Information for additional Important Safety\nInformation.\n\nForward-looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. All statements contained\nin this press release that do not relate to matters of historical fact should\nbe considered forward-looking statements, including, without limitation,\nstatements regarding the safety, efficacy, potential benefits of, and clinical\ndesign or progress of any of our products or product candidates at any dosage\nor in any indication; our participation in upcoming events and presentations,\nincluding at the upcoming Bank of America Global Healthcare Conference,\nincluding the content, date and timing of any of the foregoing. Statements\nusing words such as “expect”, “anticipate”, “believe”, “may”,\n“will” and similar terms are also forward-looking statements. Such\nstatements are subject to numerous risks, uncertainties and other important\nfactors, including those discussed under the caption “Risk Factors” in\nRhythm’s Quarterly Report on Form 10-Q for the three months ended March 31,\n2026, and our other filings with the Securities and Exchange Commission.\nExcept as required by law, we undertake no obligations to make any revisions\nto the forward-looking statements contained in this release or to update them\nto reflect events or circumstances occurring after the date of this release,\nwhether as a result of new information, future developments or otherwise.\n\nCorporate Contacts: \nDavid Connolly \nHead of Investor Relations and Corporate Communications \nRhythm Pharmaceuticals, Inc. \n857-264-4280 \ndconnolly@rhythmtx.com  \n\nKate Walsh\nDirector, Corporate Communications\nRhythm Pharmaceuticals, Inc. \n(857) 264-4280\nkwalsh@rhythmtx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b767aaa5-9915-465f-9233-d97757f4e387)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-06T12:00:00.917821291Z","server_sent_at_ms":1778068800917},"received_at":"2026-05-06T12:00:00.986Z","source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288752/0/en/rhythm-pharmaceuticals-announces-participation-in-upcoming-bank-of-america-global-healthcare-conference.html"},"analysis":{"id":"17107","press_release_id":"23031","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Rhythm Pharmaceuticals announced that CEO David Meeker will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13 in Las Vegas.\n\nThe session will be webcast live via the Investor Relations section of the company website, with a replay available for 30 days following the event.\n\nThe release includes standard company background regarding its lead asset IMCIVREE and pipeline candidates but does not contain any new operational or clinical updates.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation announcement."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"David Meeker","role":"Chairman, President and Chief Executive Officer"}],"products":["IMCIVREE","setmelanotide","bivamelagon","RM-718"],"companies":[{"name":"Rhythm Pharmaceuticals, Inc.","ticker":"RYTM","relationship":"issuer"},{"name":"Bank of America","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine logistical announcement regarding participation at an industry conference. No new financial data, clinical results, or material business developments were disclosed."},"tickerRelevance":{"others":[],"primary":"RYTM"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"newsType":"logistical","eventGravity":"conference-announcement","sectorWeight":"biotech"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Rhythm Pharmaceuticals announced that CEO David Meeker will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13 in Las Vegas.\n\nThe session will be webcast live via the Investor Relations section of the company website, with a replay available for 30 days following the event.\n\nThe release includes standard company background regarding its lead asset IMCIVREE and pipeline candidates but does not contain any new operational or clinical updates.","key_figures":{},"named_entities":{"people":[{"name":"David Meeker","role":"Chairman, President and Chief Executive Officer"}],"products":["IMCIVREE","setmelanotide","bivamelagon","RM-718"],"companies":[{"name":"Rhythm Pharmaceuticals, Inc.","ticker":"RYTM","relationship":"issuer"},{"name":"Bank of America","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:511026a279f8af46","schema_hash":"sha256:96555d0809de301c","created_at":"2026-05-06T14:55:50.373Z","global_importance":12,"audience_relevance":15,"importance_components":{"newsType":"logistical","eventGravity":"conference-announcement","sectorWeight":"biotech"}},"durationMs":159731,"modelName":"glm-4.7"}}